Inflammation blockade improves pancreatic islet function
- 1 November 2004
- journal article
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 36 (9), 2864-2865
- https://doi.org/10.1016/j.transproceed.2004.09.083
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation1Transplantation, 2004
- Inhibition of STAT4 Activation by Lisofylline Is Associated with the Protection of Autoimmune DiabetesAnnals of the New York Academy of Sciences, 2003
- Lilly Lecture 2002Diabetes, 2003
- The Novel Anti-inflammatory Compound, Lisofylline, Prevents Diabetes in Multiple Low-Dose Streptozotocin-Treated MicePancreas, 2003
- The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic miceDiabetologia, 2002
- Lisofylline, a Novel Antiinflammatory Agent, Protects Pancreatic -Cells from Proinflammatory Cytokine Damage by Promoting Mitochondrial MetabolismEndocrinology, 2002
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- Cell Loss in Isolated Human Islets Occurs by ApoptosisPancreas, 2000
- Mitochondria and ApoptosisScience, 1998
- Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid.Proceedings of the National Academy of Sciences of the United States of America, 1994